These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35406796)

  • 1. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
    Niessner H; Burkard M; Leischner C; Renner O; Plöger S; Meraz-Torres F; Böcker M; Hirn C; Lauer UM; Venturelli S; Busch C; Sinnberg T
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.
    Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T
    Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
    Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
    Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
    Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 8. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M-CSF as a therapeutic target in BRAF
    Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
    Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
    Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.
    Bokharaie H; Kolch W; Krstic A
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
    Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
    J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
    Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
    Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
    Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
    Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.